ArticleCancer research2020
5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against
Open access · greenAbstract readClinical Trial, Phase I
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
4.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 136 citations in OpenAlex.
- Rewiring redox defense: Nrf2-driven antioxidant signaling as a gateway to programmed cell death activation in colorectal cancer.Genes & diseases · 2027Review
- Neural-tumor interactions: bidirectional regulatory mechanisms and nervous system-targeted tumor therapeutic strategies.Biomarker research · 2026Review
- UPP1 in Cancer: Context-Dependent Roles in Metabolic Adaptation and Treatment Response.Current issues in molecular biology · 2026Review
- Review
- 70 Years of DON and Beyond: Glutaminase Inhibition as a Synergistic Strategy in Cancer Combination Therapy.Pharmaceutics · 2026Review
- Tumor heterogeneity: development, mechanisms, and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- A ketogenic diet sensitizes pancreatic cancer to glutamine metabolism inhibitors.Cell reports. Medicine · 2026Article
- Overview of glutamine metabolism in stromal components of the tumor microenvironment and potential anti-tumor therapies.Genes & diseases · 2026Review
- Targeting glutamine metabolism to modulate macrophage functions in the tumor microenvironment.Discover oncology · 2026Review
- Glutamine promotes acute wound healing by mediating glutamine metabolism and M2 macrophage polarization via the MEK/ERK/SLC1A5 signaling pathway.Scientific reports · 2026Article
- Enhancing 5-fluorouracil efficacy in colorectal cancer by inhibiting glutathione antioxidant mechanisms with an xCT inhibitor.Scientific reports · 2026Article
- Role of uridine phosphorylase 1 in cancer: A comprehensive pan-cancer analysis highlighting its prognostic and therapeutic potential.Medicine · 2026Article
- ACSL5 Regulates Glucose Metabolism and Chemotherapy Sensitivity in Colorectal Cancer Cells under Glutamine Deficiency.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- RHOJ derived peptide promotes chemosensitivity by inhibiting glutamine metabolism in gastric cancer.Journal of translational medicine · 2026Article
- Helicobacter pylori promotes gastric cancer progression via UPP1-mediated uridine bypass of glycolysis.Cancer cell international · 2026Article
- Understanding Liver and Digestive Diseases: A Paved Road to Improve Diagnosis, Management, and Treatment.Exploration of digestive diseases · 2026Article
- A pancancer analysis reveals the oncogenic role of glutaminase 1 (GLS1) in tumor metabolism and immune evasion: a bioinformatics analysis.Discover oncology · 2025Article
- The regulatory role and mechanism of energy metabolism and immune response in head and neck cancer.Genes & diseases · 2025Review
- CRISPR/Cas9 screenings reveal the role of STX1A and CDK1 in Cathepsin G entering and killing colorectal cancer cells.bioRxiv : the preprint server for biology · 2025Article
- Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 1 country.
Yiqing Zhao *Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio.ORCID 0000-0003-4973-3611
Xiujing Feng *Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio.
Yicheng Chen *Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio.
J Eva SelfridgeDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio.
Shashank GorityalaDepartment of Chemistry, Cleveland State University, Cleveland, Ohio.
Zhanwen DuDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio.
Janet M WangDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio.
Yujun HaoDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio.
Gino CioffiDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio.
Ronald A ConlonDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio.
Jill S Barnholtz-SloanCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.ORCID 0000-0001-6190-9304
Joel SaltzmanSeidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Smitha S KrishnamurthiSeidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Shaveta VinayakSeidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Martina VeiglCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.
Yan XuDepartment of Chemistry, Cleveland State University, Cleveland, Ohio.ORCID 0000-0003-2697-1297
David L BajorCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.ORCID 0000-0003-2702-5008
Sanford D MarkowitzCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.
Neal J MeropolCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.
Jennifer R EadsCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio. zxw22@case.edu Jennifer.Eads@pennmedicine.upenn.edu.
Zhenghe WangDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, Ohio. zxw22@case.edu Jennifer.Eads@pennmedicine.upenn.edu.
Case Western Reserve University · USUniversity Hospitals of Cleveland · USUniversity Hospitals Seidman Cancer Center · USCleveland State University · US
Funding
TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3MTargeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and PreventionP50CA150964 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARKOWITZ, SANFORD D. · 2011 to 2022
$24.6MTRANSLATIONAL RESEARCH ONCOLOGY TRAINING GRANTK12CA076917 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 1997 to 2022
$14.2MMechanisms of metabolic reprogramming by PIK3CA oncogenic mutationsR01CA196643 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Zhenghe Wang · 2016 to 2026
$3.1MNRSA Training CoreTL1TR002549 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI HARDING, CLIFFORD V · 2018 to 2022
$2.9MHigh throughput screen for GPT2 inhibitors to target PIK3CA-mutant cancersUH2CA223670 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI WANG, ZHENGHE · 2018 to 2019
$378kNCATS NIH HHS TL1 TR002549NCI NIH HHS K12 CA076917NCI NIH HHS P30 CA043703NCI NIH HHS P50 CA150964NCI NIH HHS R01 CA196643NCI NIH HHS UH2 CA223670
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAnimalsAntineoplastic Combined Chemotherapy ProtocolsBenzeneacetamidesClass I Phosphatidylinositol 3-KinasesColorectal NeoplasmsDose-Response Relationship, DrugFemaleFluorouracilHumansMaleMaximum Tolerated DoseMiceMiddle AgedThiadiazolesXenograft Model Antitumor AssaysBenzeneacetamidesCB-839Class I Phosphatidylinositol 3-KinasesFluorouracilPIK3CA protein, humanThiadiazoles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.